The Best Target & The Best Chemical


The oncogene ALK (Anaplastic Lymphoma Kinase) is a representative tyrosine kinase receptor that spans cell membranes, and mutations in this gene have been found in non-small cell lung cancer and other solid cancers in addition to lymphoma. Since then, many types of ALK inhibitors have been developed, but cancer cells induce secondary mutations or use a bypass signaling system to give resistance to ALK inhibitors. PHI-401 is a drug being developed using big data and AI-based platforms to overcome drug resistance, which is the most problematic in the treatment of ALK inhibitors.

Unmet Needs
  • About 5% of Lung
    adenocarcinoma patients
    have ALK mutation

  • Needs to develop Best-in-Class
    target anticancer drugs that are
    effective for NPM-ALK,
    EML4-ALK fusion as well as
    various ALK-resistant mutants.


The Best-in-Class ALK kinase inhibitor with overcoming resistant ALK mutants (L1196M, G1202R)

  • ALK resistant mutants
  • Number of patients About 21,000 people (2025)
  • Market size KRW 2.9T (2023) Target Market
    • Lung adenocarcinoma patients with ALK mutations

Sources : 2018, Datamonitor Healthcare report, “NSCLC: epidemiology” Nature Reviews Drug Discovery 15 , 229-230 (2016)